Artificial intelligence (machine learning and deep learning, to be more specific) has become widely discussed topics in the area of life sciences and healthcare over the last several years and the excitement keeps growing. While a lot of pharmaceutical companies and healthcare organizations express considerable interest in possible new opportunities, associated with the use of artificial intelligence for early drug discovery, clinical trial optimization, and business intelligence, a considerable gap still exists when it comes to understanding new technologies by pharmaceutical professionals and leaders. The key questions here are these:
What machine learning / AI can and can’t do for the pharmaceutical industry
What should be done to harness practical and measurable value out of machine learning / AI?
How it should be done and what are the timelines for getting returns on investments?